Table IV.
Immunohistochemical characteristics of the GIST series.
| Tumor site | |||||
|---|---|---|---|---|---|
| Characteristics | Esophagus | Stomach | Small intestine | Rectum | All sites |
| Bcl-2a | |||||
| I | 0.5 (0.5) | 1.9 (2.0) | 2.6 (3.0) | 1.8 (1.5) | 2.1 (2.0) |
| E | 5 (5.0) | 70 (80.0) | 86 (90.0) | 58 (60.0) | 74 (90) |
| S | 5±7 | 158±98 | 236±84 | 123±117 | 178±102 |
| CD117 (C-kit)a | |||||
| I | 1.8 (1.8) | 2.0 (2.0) | 2.5 (3.0) | 2.6 (2.8) | 2.2 (2.0) |
| E | 58 (57.5) | 79 (95.0) | 93 (100.0) | 99 (100.0) | 84 (100.0) |
| S | 109±101 | 183±101 | 236±89 | 260±49 | 202±99 |
| CD34a | |||||
| I | 1.8 (1.8) | 2.4 (3.0) | 1.7 (2.0) | 2.5 (2.5) | 2.2 (2.5) |
| E | 50 (50.0) | 81 (100.0) | 52 (45.0) | 96 (97.5) | 72 (95.0) |
| S | 95±92 | 220±106 | 126±117 | 239±45 | 189±117 |
| CD44 | |||||
| I | 0.5 (0.5) | 0.7 (1.0) | 1.0 (1.0) | 0.5 (0.5) | 0.8 (1.0) |
| E | 3 (2.5) | 25 (10.0) | 34 (30.0) | 13 (10.0) | 27 (20.0) |
| S | 3±4 | 39±64 | 62±92 | 13±15 | 46±75 |
| Desmina | |||||
| I | 1.0 (1.0) | 0.3 (0.0) | 0.2 (0.0) | 0.4 (0.0) | 0.3 (0.0) |
| E | 48 (47.5) | 4 (0.0) | 3 (0.0) | 2 (0.0) | 4 (0.0) |
| S | 95±134 | 6±19 | 7±37 | 2±3 | 7±29 |
| DOG-12 | |||||
| I | 1.5 (1.5) | 1.6 (1.5) | 2.2 (2.0) | 2.5 (2.5) | 1.8 (2.0) |
| E | 48 (47.5) | 70 (80.0) | 86 (100.0) | 91 (97.5) | 75 (90.0) |
| S | 87±103 | 133±92 | 209±94 | 231±75 | 160±99 |
| Ki-67 (/mm2)b | |||||
| Median (range) | 47.2 (44–50) | 122 (16–2,011) | 133 (22–1,322) | 161 (0–377) | 127 (0–2,011) |
| Mean ± SD | 47.2±3.8 | 165±210 | 227±255 | 152±149 | 184±226 |
| PDGFRα | |||||
| I | 1.0 (1.0) | 1.8 (2.0) | 1.9 (2.0) | 0.9 (1.0) | 1.8 (2.0) |
| E | 45 (45.0) | 77 (85.0) | 83 (90.0) | 58 (70.0) | 78 (85.0) |
| S | 45±49 | 150±88 | 154±79 | 68±55 | 148±85 |
| PHH3 per 50 HPFs | |||||
| Median (range) | 3.5 (0–7) | 11 (0–605) | 15 (1–219) | 7 (3–15) | 13 (0–605) |
| Mean ± SD | 3.5±4.9 | 27.3±77.3 | 29.6±42.6 | 8.3±6.1 | 27.6±66.3 |
| P16 | |||||
| I | 0.5 (0.5) | 0.6 (0.0) | 0.9 (1.0) | 0.7 (1.0) | 0.7 (0.5) |
| E | 20 (20.0) | 11 (0.0) | 21 (10.0) | 15 (5.0) | 14 (2.5) |
| S | 20±28 | 17±38 | 36±69 | 15±22 | 23±50 |
| P53 | |||||
| I | 0.0 (0.0) | 0.4 (0.0) | 0.5 (0.0) | 0.3 (0.0) | 0.4 (0.0) |
| E | 0 (0.0) | 6 (0.0) | 11 (0.0) | 5 (0.0) | 8 (0.0) |
| S | 0±0 | 7±15 | 17±41 | 5±10 | 10±27 |
| SMAa | |||||
| I | 1.5 (1.5) | 0.6 (0.0) | 1.0 (1.0) | 0.5 (0.5) | 0.7 (1.0) |
| E | 50 (50.0) | 11 (0.0) | 23 (10.0) | 4 (2.5) | 15 (5.0) |
| S | 150±212 | 18±43 | 39±56 | 4±5 | 26±52 |
| S-100 | |||||
| I | 0.0 (0.0) | 0.2 (0.0) | 0.2 (0.0) | 0.4 (0.0) | 0.2 (0.0) |
| E | 0 (0.0) | 3 (0.0) | 3 (0.0) | 2 (0.0) | 3 (0.0) |
| S | 0±0 | 5±22 | 6±38 | 2±3 | 5±28 |
I and E are expressed as mean (median); S is expressed as mean ± SD.
a
Significant differences between GIST sub-localizations using analysis of variance.
b
Analyzed as previously described (15). GIST, gastrointestinal stromal tumor; I, intensity; E, extent; S, quickscore; HPFs, high-power fields; SD, standard deviation; Bcl-2, B-cell lymphoma 2; DOG-1, discovered on GIST 1; PDGFRα, platelet-derived growth factor receptor α; PHH3, phosphohistone H3; SMA, smooth muscle actin.